GlassScriptPhysician profile
Sidrah Khan
NPI 1073280434
$4,845.77
in general payments reported to CMS, 2019-2025
28 companies · $968 in 2025
The $968 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $379 · 2023: $1,235 · 2024: $2,264 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,458 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,458.16 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $895.29 | 2022-2025 | |
| Pfizer INC. | $763.67 | 2023-2025 | |
| Novo Nordisk INC | $581.05 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Viiv Healthcare Company | $503.42 | 2023-2025 | Apretude |
| Amgen INC. | $459.35 | 2023-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $366.39 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| E.R. Squibb & Sons, L.L.C. | $133.53 | 2023-2025 | Eliquis |
| Gilead Sciences, INC. | $126.26 | 2022-2025 | |
| Inspire Medical Systems, INC. | $107.18 | 2023-2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.63 | 2023-2025 | Xifaxan |
| Astellas Pharma US INC | $101.46 | 2023-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $99.77 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Lundbeck LLC | $85.22 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $75.37 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $64.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $56.30 | 2024 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company LTD. | $51.08 | 2022 | |
| Bausch Health US, LLC | $41.67 | 2024 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $34.53 | 2025 | Trintellix |
| Dexcom, INC. | $29.06 | 2025 | Dexcom G6 Transmitter |
| Upsher-Smith Laboratories LLC | $27.12 | 2022 | |
| Hologic Sales and Service, LLC | $23.56 | 2024 | Aptima |
| Vivus LLC | $21.76 | 2024 | Qsymia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.19 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $19.11 | 2022 | |
| Sanofi Pasteur INC. | $19.10 | 2023 | |
| Coopersurgical, INC. | $18.58 | 2022 | |
| Watermark Medical, INC. | $15.64 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidrah Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.